XML 43 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt - Long-Term Debt from Royalty-Bearing Instrument-December 2012 Financing - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Dec. 06, 2012
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Debt Disclosure [Line Items]            
Gain (loss) on change in fair value of derivative liabilities     $ 3,610,000   $ 8,170,000  
Long-term debt from royalty-bearing instrument, carrying amount net of unamortized discount   $ 95,183,000   $ 95,183,000   $ 93,592,000
BioPharma Debt            
Debt Disclosure [Line Items]            
Amount received at the closing of the agreement $ 100,000,000          
Maximum repayment of future revenue and receivables 150,000,000 113,800,000   113,800,000    
Repayment under agreement   4,500,000   11,800,000    
Fair value of embedded derivative liability $ 14,600,000          
Gain (loss) on change in fair value of derivative liabilities       0 5,500,000  
Long-term debt from royalty-bearing instrument, carrying amount net of unamortized discount   95,200,000   95,200,000   $ 93,600,000
BioPharma Debt | Cash            
Debt Disclosure [Line Items]            
Interest expense, contractual coupon interest       4,800,000 5,000,000  
BioPharma Debt | Non Cash            
Debt Disclosure [Line Items]            
Convertible notes, interest expense       1,600,000 $ 1,500,000  
BioPharma Debt | May 2017            
Debt Disclosure [Line Items]            
Future minimum repayment under agreement   $ 4,700,000   $ 4,700,000